Setting new standards in schizophrenia outcomes: Symptomatic remission 3 years before versus after the andreasen criteria

详细信息	查看全文 | 推荐本文 |

• 作者：P. Gorwood^a ; ^b ; J. Peuskens^c ; ^{jozef.peuskens@uc-korenberg.be} ; on behalf of the EGOFORS initiative (European Group On Functional Outcomes ; Remission in Schizophrenia)
• 关键词：Schizophrenia ; Remission ; Criteria ; Functioning ; Quality of life
• 刊名：European Psychiatry
• 出版年：2012
• 期刊代码：96_09249338
• 类别：med
• 出版时间：April, 2012
• 卷：27
• 期：3
• 页码：170-175
• 文件大小：316 K

摘要

Symptomatic remission is often mentioned as one of the treatment goals for schizophrenia. However, the consistently with which this is documented in the schizophrenia literature since the introduction of the consensus criteria proposed by Andreasen and colleagues in 2005 has yet to be investigated. Similarly, additional treatment goals which are being discussed include improved functioning and quality of life, but whether these goals are being increasingly documented in the literature alongside symptomatic remission is as yet unknown. The objective of this article is therefore to review the use of the term 鈥榬emission鈥?in the schizophrenia literature from Europe, USA and the rest of the world from 2002 to 2007, before and after the introduction of the Andreasen criteria. A second objective is to determine whether these manuscripts documenting symptomatic remission are also addressing other concepts such as functioning, quality of life and relationships. This literature review indicates that the use of the Andreasen criteria is indeed increasing, although there are manuscripts documenting alternative remission criteria or using the term remission without documentation of specific remission criteria. From 2004 to 2007 the number of manuscripts mentioning remission without documenting specific criteria has fallen by approximately 50%. Within these manuscripts there is increasing awareness of functioning and quality of life as outcome measures, in particular in manuscripts generated in Europe and the USA. This review highlights the growing importance of co-assessment of symptomatic remission and functional outcomes, and calls for further consideration of the most appropriate and consistent way to evaluate functioning of schizophrenia patients.